RxDoctor Payments Data

Thomas Slabaugh, MD

Urology · Lexington, KYNPI 1174622120

Payments from drug & device makers

What this record shows

This record is dominated by other: $91,000 of the $101,721 with a category attached, or 89.5%. Angiodynamics, Inc. accounts for 91.1% of it on its own, with 49 other manufacturers making up the rest. 2025 is the largest year on record at $62,313, more than ten times the $1,032 reported in 2019. Among urology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$101,721in general payments, 2019–2025

Across 307 payments — averaging $331.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$93K
  • Boston Scientific$1K
  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$953
  • Procept Biorobotics Corporation$700
  • Accord Healthcare, Inc.$389
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$1,2331%
  • Food & beverage$9,0689%
  • Education$4210%
  • Other$91,00089%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,721 in reported general payments places this provider in the 95th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$438,386
Medicare patients
1,342
Services billed
19,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide67$954,491
GemtesaVibegron90$115,720
MyrbetriqMirabegron112$98,032
Methenamine Hippurate396$40,639
Alfuzosin Hcl ErAlfuzosin Hcl793$15,384
Mirabegron ErMirabegron15$15,272
Solifenacin Succinate142$9,418
Finasteride706$7,811
Tamsulosin Hcl511$5,789
Testosterone27$4,598
Bicalutamide104$4,490
Potassium Citrate ErPotassium Citrate48$4,312
Doxycycline Monohydrate380$3,793
Bethanechol Chloride48$3,710
Trospium Chloride ErTrospium Chloride13$3,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$953$1,052,524179 claims
Sumitomo Pharma America, Inc.Gemtesa$335$115,72090 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 139 urology providers in Kentucky.

Other urology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →